eligibility assessment for intravenous thrombolytic therapy in acute ischemic stroke patients; evaluating barriers for implementation

Authors

hormoz ayromlou department of neurology, tabriz university of medical sciences, tabriz, ir iran

hassan soleimanpour department of emergency, tabriz university of medical sciences, tabriz, ir iran

mehdi farhoudi department of neurology, tabriz university of medical sciences, tabriz, ir iran

aliakbar taheraghdam

abstract

conclusions: the major barriers for thrombolytic therapy for patients with ais in this setting were delays in the provision of in-hospital services, like initial patient assessment, ct scans or laboratory studies. these results were in contrast with previous reports. background: intravenous thrombolysis is an approved treatment method for patients with acute ischemic stroke (ais) and is recommended by multiple guidelines. however, it seems that it is less frequently used in the developing countries compared to the developed countries. objectives: the purpose of this study was to estimate the percentage of patients with ais, eligible for intravenous thrombolytic therapy, at the main referral center in northwest iran and to determine the main barriers for implementation of this method. patients and methods: over one year, 647 patients who were admitted to the emergency department and met the cincinnati stroke scale were enrolled into the study. the center to which patients were admitted, is a tertiary university hospital that has the required infrastructure for thrombolytic therapy in ais. factors recorded were neurological examinations and time between onset of symptoms and hospital arrival, hospital arrival and performance of brain computed tomography (ct) scanning, and hospital arrival to complete the investigations. patients eligible for intravenous thrombolytic therapy were identified according to the american heart association (aha) guidelines. results: mean time interval between hospital arrival and completion of brain ct scanning was 91 minutes (range: 20–378 minutes) and mean time from hospital arrival to completion of investigations was 150 minutes (range: 30–540 minutes). a total of 159 (31.3%) patients arrived at hospital within 3 hours of the onset of symptoms (early enough for intravenous thrombolytic therapy). however, 81.7% (130/159) of these patients missed thrombolytic therapy due to delayed performance of brain ct scanning and laboratory tests and 38.3% (61/159) had contraindications. the remaining 16 patients (10% of those who arrived within 3 hours and 3.1% of all cases) were eligible for thrombolytic therapy.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Eligibility Assessment for Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients; Evaluating Barriers for Implementation

BACKGROUND Intravenous thrombolysis is an approved treatment method for patients with acute ischemic stroke (AIS) and is recommended by multiple guidelines. However, it seems that it is less frequently used in the developing countries compared to the developed countries. OBJECTIVES The purpose of this study was to estimate the percentage of patients with AIS, eligible for intravenous thrombol...

full text

Intravenous thrombolytic therapy for acute ischemic stroke.

n engl j med 364;22 nejm.org june 2, 2011 2138 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented...

full text

Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke

  Background: Thrombolytic therapy is the only approved treatment for acute cerebral ischemia. The hemorrhagic transformation is the greatest complication of this treatment, which may occur after recanalization of occluded artery. The aim of this study was to determine factors associated with clinical improvement and worsening in patients with acute ischemic stroke treated with intravenous th...

full text

Intravenous Thrombolytic Therapy for Acute Ischemic Stroke

n engl j med 364;22 nejm.org june 2, 2011 2138 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented...

full text

retrosternal mass: an interesting allergic reaction to intravenous thrombolytic therapy for acute ischemic stroke.

stroke is an important cause of disability and death worldwide, with the majority of strokes occurring in older people. thrombolysis with recombinant tissue plasminogen activator (r-tpa) is the approved treatment for acute ischemic stroke. a major concern of physicians, who treat acute ischemic stroke with recombinant tissue plasminogen activator (r-tpa,) is the risk of intracerebral hemorrhage...

full text

safety and feasibility of intravenous thrombolytic therapy in iranian patients with acute ischemic stroke

background: thrombolytic therapy is the only approved treatment for acute cerebral ischemia. the hemorrhagic transformation is the greatest complication of this treatment, which may occur after recanalization of occluded artery. the aim of this study was to determine factors associated with clinical improvement and worsening in patients with acute ischemic stroke treated with intravenous thromb...

full text

My Resources

Save resource for easier access later


Journal title:
iranian red crescent medical journal

جلد ۱۶، شماره ۵، صفحات ۰-۰

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023